On January 13, 2023, Zhejiang Jiuzhou Pharmaceutical Co., Ltd closed the transaction. The company has issued 65,291,198 shares at a price of CNY 38.29 per share for gross proceeds of CNY 2,499,999,971.42. The company has paid issuance expenses of CNY 11,562,925.99 and received net proceeds of CNY 2,488,437,045.43 in the transaction.

The transaction included participation from GF Fund Management Co., Ltd. for 4,021,937 shares, JIC Investment Co., Ltd. for 1,828,153 shares, Fullgoal Fund Management Co., Ltd. for 1,828,153 shares, Taikang Life Insurance Co., Ltd. for 8,017,757 shares, Guotai Junan Securities Co., Ltd. for 4,230,869 shares, Linhai Financial Investment Co., Ltd. for 1,854,270 shares, ICBC Credit Suisse Asset Management Co., Ltd. for 8,252,807 shares, E Fund Management Co., Ltd. for 2,689,997 shares, Nuode Asset Management Co., Ltd. for 1,828,153 shares, China Petrochemical Corporation, Enterprise Annuity Plan for 1,854,270 shares, Changjiang Pension Insurance Co., Ltd. for 1,854,270 shares, Jinan Jiangshan Investment Partnership Enterprise (Limited Partnership) for 5,223,295 shares, China Merchants Fund Management Co.,Ltd. for 3,577,957 shares, UBS AG for 2,454,949 shares, Caitong Fund Management Co., Ltd. for 1,828,153 shares, CITIC Securities Company Limited for 1,802,048 shares, Dacheng Fund Management Company Limited for 4,831,548 shares, Shanghai Shenchuang New Power Equity Investment Fund Partnership Enterprise (L.P.) managed by Shanghai Junhe Licheng Investment Management Center (Limited Partnership) for 1,828,153 shares, China Life Insurance Assets Management Co. Ltd. for 1,828,153 shares and Shanghai Shenchuang Chancheng Private Fund Partnership Enterprise (Limited Partnership) for 1,828,153 shares.